CGEN:TLV
Compugen Ltd
ILAÂ 766.40
arrow_downward
-2.86%(-22.60) 1D
Sep 4, 5:26:00 PM GMT+3 · ILA
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CGEN...
Open
ILAÂ 789.00
High
ILAÂ 795.40
Low
ILAÂ 766.40
Mkt. cap
244.87M
Avg. vol.
41.40K
Volume
14.93K
P/E ratio
6.95
52-wk high
ILAÂ 924.00
52-wk low
ILAÂ 435.00
EPS
ILAÂ 1.10
Shares outstanding
94.73M
No. of employees
75
Open
ILAÂ 789.00
High
ILAÂ 795.40
Low
ILAÂ 766.40
Mkt. cap
244.87M
Avg. vol.
41.40K
Volume
14.93K
P/E ratio
6.95
52-wk high
ILAÂ 924.00
52-wk low
ILAÂ 435.00
EPS
ILAÂ 1.10
Shares outstanding
94.73M
No. of employees
75
Profile
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. Wikipedia
About Compugen Ltd